Key result
Pediatric trials of antihypertensive agents are more likely to succeed when utilizing weight-based dosing, liquid formulations, appropriate dose ranges, and suitable blood pressure endpoints.
Optimizing trial design with weight-based dosing, liquid formulations, and appropriate endpoints improves the success rate of pediatric antihypertensive trials.
Answers are grounded in this paper and cite their sources.
May guide future pediatric antihypertensive trial designs; leaves open effects on approvals and clinical outcomes.
There is an increasing prevalence of pediatric hypertension worldwide due to the growing epidemic of childhood obesity. Recent regulatory changes in the USA and Europe have stimulated major pediatric clinical trials of 16 different antihypertensive agents, leading to US FDA labeling of 10 of these drugs. With increased pediatric hypertension trial experience, trial designs have been refined and we now better understand factors associated with trial success, including the ability to differentiate a dose–response relationship. The use of weight-based dosing and liquid formulation of study drug, selection of an appropriate dose range and appropriate blood pressure end points all increase the likelihood of pediatric trial success.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2014) conducted a review in Pediatric hypertension. Antihypertensive agents was evaluated. Pediatric trials of antihypertensive agents are more likely to succeed when utilizing weight-based dosing, liquid formulations, appropriate dose ranges, and suitable blood pressure endpoints.
Synapse has enriched 10 related papers. Consider them for comparative context: